Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:
H.C. Wainwright BioConnect 2022 Virtual Conference
Presentation Date: Monday, January 10, 2022
Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET
2022 B Riley Virtual Oncology Conference
Fireside Chat Live Webcast Date: Thursday, January 27, 2022
Time: 10:30 AM ET
The live and on demand webcasts of both presentations will be available on the Company's website at www.vobrbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Sarah Spencer
Vice President, Corporate Communications, Vor
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.33 |
| Daily Change: | -0.03 -2.21 |
| Daily Volume: | 359,472 |
| Market Cap: | US$165.640M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
